Specific protection against breast cancers by cyclin D1 ablation

Nature

Volumn 411, Issue 6841, 2001, Pages 1017-1021

  Yu, Q ^a   Geng, Y ^a   Sicinski, P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; GENES; ONCOLOGY; TISSUE;

BREAST CANCERS;

TUMORS;

CYCLIN D1; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER INCIDENCE; CELL CYCLE; CONTROLLED STUDY; FEMALE; GENE TARGETING; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE C MYC; ONCOGENE NEU; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CROSSES, GENETIC; CYCLIN D1; FEMALE; GENES, BCL-1; GENES, ERBB-2; GENES, MYC; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED; WNT PROTEINS; WNT1 PROTEIN; ZEBRAFISH PROTEINS;

ANIMALIA; MUS MUSCULUS;

EID: 0035963435     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35082500     Document Type: Article

References (31)

1. CDK inhibitors: Positive and negative regulators of G1-phase progression
2. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer
3. Cyclin D1 protein expression and function in human breast cancer
4. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining
5. Determination of the prognostic value of cyclin D1 overexpression in breast cancer
6. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions
7. Cyclin D1 and prognosis in human breast cancer
8. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
9. Cyclin D1 provides a link between development and oncogenesis in the retina and breast
10. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development
11. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo
12. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
13. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
14. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice
15. Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation
16. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
17. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis
18. Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line
19. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types
20. Activation of the Ras signaling pathway in human breast cancer cells overexpressing erbB-2
21. Induction of cyclin D1 overexpression by activated ras
22. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
23. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells
24. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway
25. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway
26. Rescue of cyclin D1 deficiency by knockin cyclin E
27. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins
28. Involvement of Myc activity in a G1/S-promoting mechanism parallel to the pRb/E2F pathway
29. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo
30. Genetic alterations in breast cancer
31. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185